Biotech entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Amy Arnott, the most common co-covered peer. The tracked stories average 3 original sources each. Ark Investment Management appears in 1 tracked Biotech story from March 16, 2026.
Last mentioned: Mar 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Amy Arnott, the most common co-covered peer. The tracked stories average 3 original sources each. Ark Investment Management appears in 1 tracked Biotech story from March 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ark Investment Management. Shared-story counts are live from our verified record — not editorial picks.
Cathie Wood's ARK Investment Management has purchased $2 million worth of Tempus AI shares, reinforcing its position in the precision medicine firm despite a 15% year-to-date decline. The move underscores Wood's commitment to 'coiled spring' AI and biotech assets, even as her flagship funds face significant performance headwinds compared to the broader market.
Source: Kansascity · Miamiherald
Ark Investment Management is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
